Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet (London, England) · 2024 · 686 citations · Sajeve Thomas
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
The New England journal of medicine · 2023 · 739 citations · Yuanbin Chen, Jose Najera
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
Lancet (London, England) · 2023 · 534 citations · Yuanbin Chen
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
The New England journal of medicine · 2024 · 289 citations · Yuanbin Chen
Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.
European urology · 2024 · 150 citations · John Graham
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
The Lancet. Oncology · 2021 · 600 citations · Yuanbin Chen
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
ESMO open · 2022 · 302 citations · Yuanbin Chen
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Journal for immunotherapy of cancer · 2022 · 311 citations · Sajeve Thomas